The Efficacy and Safety of Nucleos(t)ide Analogues in Patients with Spontaneous Acute Exacerbation of Chronic Hepatitis B: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Yu, Weiyan ^a   Zhao, Caiyan ^a   Shen, Chuan ^a   Wang, Yadong ^a   Lu, Hongzhi ^a   Fan, Jing ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FAILURE; MORTALITY; OUTCOMES RESEARCH; QUANTITATIVE STUDY; SHORT TERM SURVIVAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

ANIMALS; ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE;

HEPATITIS B VIRUS;

EID: 84878929485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065952     Document Type: Article

References (34)

1. Lok AS, McMahon BJ, (2009) Chronic hepatitis B: update 2009. Hepatology 50: 661-662.
2. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167-185.
3. Seeff LB, Koff RS, (1986) Evolving concepts of the clinical and serologic consequences of hepatitis B virus infection. Semin Liver Dis 6: 11-22.
4. Lok AS, Lai CL, (1990) Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 10: 29-34.
5. Matsumoto K, Miyake Y, Miyatake H, Takahara M, Imada T, et al. (2009) A combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B. World J Gastroenterol. 15: 1650-1652.
6. Chien RN, Lin CH, Liaw YF, (2003) The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 38: 322-327.
7. Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, et al. (2005) Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 20: 426-432.
8. Tsubota A, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, et al. (2001) Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study. Am J Gastroenterol 96: 557-562.
9. Lv GC, Ma WJ, Ying LJ, Jin X, Zheng L, et al. (2010) Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. World J Gastroenterol 16: 4095-4099.
10. Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, et al. (2011) Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol. 54: 236-242.
11. Peng CY, Chen CB, Lai HC, Su WP, Chuang PH, et al. (2011) Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation. Hepatol Int 5: 586-596.
12. Chien RN, Liaw YF, Atkins M, (1999) Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 30: 770-774.
13. Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, et al. (2008) Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Antivir Ther. 13: 571-579.
14. Sheu MJ, Kuo HT, Lin CY, Koay LB, Lee C, et al. (2009) Lamivudine monotherapy for chronic hepatitis B infection with acute exacerbation revisited. Eur J Gastroenterol Hepatol 21: 447-451.
15. Lee CM, Ong GY, Lu SN, Wang JH, Liao CA, et al. (2002) Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 37: 669-674.
16. Akuta N, Tsubota A, Suzuki F, Suzuki Y, Hosaka T, et al. (2003) Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis - an open-cohort study. J Hepatol 38: 91-97.
17. Chan HL, Tsang SW, Hui Y, Leung NW, Chan FK, et al. (2002) The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat 9: 424-428.
18. Chan HL, Wong VW, Hui AY, Tsang SW, Chan JL, et al. (2006) Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antivir Ther. 11: 465-471.
19. Chen JJ, Lin CY, Sheu MJ, Kuo HT, Sun CS, et al. (2006) Poor response to 18-month lamivudine monotherapy in chronic hepatitis B patients with IgM anti-HBc and acute exacerbation. Aliment Pharmacol Ther 23: 85-90.
20. Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, et al. (2008) A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. Liver Int 28: 1034-1041.
21. Kanda T, Shinozaki M, Kamezaki H, Wu S, Nakamoto S, et al. (2012) Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B. Int J Med Sci. 9: 27-32.
22. Liaw YF, Kao JH, Piratvisuth Ta, Chan HY, Chien RN, et al. (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012. DOI 10.1007/s12072-012-9365-4.
23. Wong VW, Chan HL, (2009) Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. J Gastroenterol Hepatol 24: 1179-1186.
24. Tsang SW, Chan HL, Leung NW, Chau TN, Lai ST, et al. (2001) Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment Pharmacol Ther 15: 1737-1744.
25. Sheen IS, Liaw YF, Tai DI, Chu CM, (1985) Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 89: 732-735.
26. Liaw YF, Chen JJ, Chen TJ, (1990) Acute exacerbation in patients with liver cirrhosis: a clinicopathological study. Liver 10: 177-184.
27. Fujiwara K, Yokosuka O, Kojima H, Kanda T, Saisho H, et al. (2005) Importance of adequate immunosuppressive therapy for the recovery of patients with "life-threatening". severe exacerbation of chronic hepatitis B. World J Gastroenterol 11: 1109-1114.
28. Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, et al. (2008) Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 43: 711-719.
29. Jeng WJ, Sheen IS, Liaw YF, (2010) Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol. 8: 541-545.
30. Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, et al. (2012) Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol 47: 1022-1029.
31. Scaglione SJ, Lok AS (2012) Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 142: 1360-1368 e1361.
32. Yao GB, Zhu M, Cui ZY, Wang BE, Yao JL, et al. (2009) A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis 10: 131-137.
33. Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, et al. (2009) Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 51: 11-20.
34. Fung J, Lai CL, Young J, Wong DK, Yuen J, et al. (2011) Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 106: 1766-1773.